|
mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study. |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Novartis; pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Menarini; Novartis; Servier |
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Lilly (Inst); Menarini; Novartis (Inst); Pfizer (Inst); Sanofi (Inst); SERVIER (Inst) |
Speakers' Bureau - Amgen; Novartis |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
Other Relationship - Roche |
|
|
Travel, Accommodations, Expenses - Eisai; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Novartis |
Consulting or Advisory Role - Seagen |
Research Funding - Lilly; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer |
|
|
Honoraria - AstraZeneca; NanoString Technologies; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Novartis; Pfizer; Roche/Genentech |
Research Funding - Novartis (Inst); pfizer (Inst) |
Travel, Accommodations, Expenses - Lilly; Lilly; Novartis; pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche |